Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vascular Biogenics Ltd. (NASDAQ: VBLT).

Full DD Report for VBLT

You must become a subscriber to view this report.


Recent News from (NASDAQ: VBLT)

VBL Therapeutics' (VBLT) CEO Dror Harats on Q1 2018 Results - Earnings Call Transcript
VBL Therapeutics (VBLT) Q1 2018 Results Earnings Conference Call May 17, 2018, 08:30 AM ET Executives Michael Wood - LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief financial Officer Analysts Swayampakula Ramakanth - H.C. Wainwright Sam Slutsky - L...
Source: SeekingAlpha
Date: May, 17 2018 13:53
VBL Therapeutics misses by $0.04, beats on revenue
VBL Therapeutics (NASDAQ: VBLT ): Q1 EPS of -$0.24 misses by $0.04 . More news on: VBL Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 07:01
VBL Therapeutics Announces First Quarter 2018 Financial Results
Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, May 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today ...
Source: GlobeNewswire
Date: May, 17 2018 07:00
VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15
TEL AVIV, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will present data on its novel MOSPD2 progra...
Source: GlobeNewswire
Date: May, 07 2018 09:00
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17
TEL AVIV, Israel, May 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio w...
Source: GlobeNewswire
Date: May, 01 2018 08:00
VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR
TEL AVIV, Israel, April 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated killing of cancer cells through binding to a tumor membrane receptor, MOSPD2. Data are p...
Source: GlobeNewswire
Date: April, 16 2018 09:00
VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16
TEL AVIV, Israel, April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company will present new data on MOSPD2, ...
Source: GlobeNewswire
Date: April, 10 2018 08:00
VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority
TEL AVIV, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million) by the Israel Innovation Authority (IIA).  The funds will support the development of the ...
Source: GlobeNewswire
Date: April, 09 2018 08:00
VBL Therapeutics' (VBLT) CEO Dror Harats on Q4 2017 Results - Earnings Call Transcript
VBL Therapeutics (VBLT) Q4 2017 Earnings Conference Call March 15, 2018 8:30 AM ET Executives Michael Wood – LifeSci Advisors Dror Harats – Chief Executive Officer Amos Ron – Chief financial Officer Analysts Charles Duncan – Piper Jaffrey Swaya...
Source: SeekingAlpha
Date: March, 15 2018 14:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-141.751.751.751.7040,751
2018-08-131.801.701.801.7054,910
2018-08-101.751.751.801.70152,680
2018-08-091.701.701.751.6535,564
2018-08-081.751.701.75351.60355,784

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-142,85416,66717.1237Cover
2018-08-1314,23336,19539.3231Short
2018-08-1027,85777,48935.9496Short
2018-08-092,08713,64415.2961Cover
2018-08-08111,824208,38953.6612Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VBLT.


About Vascular Biogenics Ltd. (NASDAQ: VBLT)

Logo for Vascular Biogenics Ltd. (NASDAQ: VBLT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: VBLT)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 27 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 26 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: February, 21 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: January, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 03 2018
      Amendment to a previously filed F-3
      Filing Type: F-3/AFiling Source: edgar
      Filing Date: January, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: VBLT)

      Daily Technical Chart for (NASDAQ: VBLT)


      Stay tuned for daily updates and more on (NASDAQ: VBLT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: VBLT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VBLT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VBLT and does not buy, sell, or trade any shares of VBLT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/